Saturday 17 October 2026 Export BIO’s income statement to Excel — free account

Bio-Rad Laboratories, Inc.

Bio-Rad Laboratories, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.6 billion, up 0.65% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 19.0%, free cash flow fell 6.06% and total debt was flat, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

353.70 11.12 −3.05%

Follow BIO

Alert me

Market cap: $9.8B
P/E: 42.5×
Fwd P/E: 35.4×
Dividend yield: —
F-score: 5/9
Altman Z: 3.20
Beneish M: −2.29
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 0.35

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	1	—	—	—	—	—	1	—	—	—	—	—

Insider Ownership 33.30%

Capital & Financial Ratios $m

Market Cap 9,760.00

Revenue 2,589.30

Net Income 318.30

Free Cash Flow 353.10

Net Debt (414.80)

Current Ratio 3.14

Debt/Equity 0.17

P/E ratio 42.46

Fwd P/E 35.40

P/S ratio 3.65

P/B ratio 1.32

Past 5Y EPS Growth (26.08%)

This Y EPS Growth (1.71%)

Next Y EPS Growth 5.08%

Next Y revenue growth (0.55%)

Next 5Y EPS Growth 5.06%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/E against its own 10 years 70.70%

10-year low 10-year high

P/S against its own 10 years 46.92%

10-year low 10-year high

P/B against its own 10 years 26.83%

10-year low 10-year high

EV/Sales against its own 10 years 47.07%

10-year low 10-year high

EV/FCF against its own 10 years 14.57%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	1,613	1,665	1,541	1,619
Receivables	489	453	461	442
Inventory	781	760	741	781
Other	26	31	28	32
	3,048	3,030	2,906	3,021

	2023	2024	2025	Q'26
Payables	145	122	129	144
ST’ Debt	1	1	1	401
Other	162	147	142	159
	523	468	517	961

Compound Annual Growth %

	10y	5y	3y
Sales	2.49%	0.29%	(2.68%)
Cash Flow	11.07%	(1.87%)	39.89%
Earnings	21.41%	(27.58%)	0.00%
Book Value	11.59%	(5.48%)	(8.14%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	592	651	—	—	—
’25	585	652	653	693	2,583
’24	611	639	650	668	2,567
’23	677	681	632	681	2,671
’22	700	691	681	730	2,802
’21	727	716	747	733	2,923
’20	572	537	647	790	2,546

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	108	99	—	—	—
’25	130	117	121	165	532
’24	70	98	164	124	455
’23	98	98	98	81	375
’22	50	53	11	80	194
’21	114	155	230	171	669
’20	63	92	136	294	585

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	78	67	—	—	—
’25	96	71	89	119	375
’24	30	55	123	81	290
’23	62	63	54	39	218
’22	17	36	(17)	43	80
’21	94	131	196	115	536
’20	41	74	116	249	480

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(19.55)	13.85	—	—	—
’25	2.29	11.67	(12.70)	26.65	27.85
’24	13.45	(76.26)	23.34	(25.57)	(65.36)
’23	2.32	(39.59)	3.64	12.14	(21.82)
’22	(112.57)	(31.12)	(5.52)	27.78	(121.79)
’21	32.38	30.32	129.96	(52.59)	140.56
’20	22.72	32.15	43.64	27.81	126.20

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	122.03	181.87	220.05	223.89	309.38	545.00	344.63	261.59	262.12	211.43	Analyst estimates 2026–2028 Powerpack
	High	184.89	273.87	345.15	376.43	648.39	832.70	752.17	509.62	387.99	373.69
People
People	Employees	8,250	3,270	8,260	8,120	8,000	7,900	8,200	8,030	7,700	7,450
	Revenue/emp, $m	0.25	0.66	0.28	0.28	0.32	0.37	0.34	0.33	0.33	0.35
Income, $m
Income, $m	Revenue	2,068	2,160	2,289	2,312	2,546	2,923	2,802	2,671	2,567	2,583
	Gross margin, %	55.05	54.98	53.43	54.38	56.48	56.05	55.93	53.42	53.73	51.87
	EBT	42	98	513	2,261	4,918	5,449	(4,704)	(850)	(2,342)	996
	EBT margin, %	2.01	4.53	22.39	97.81	193.19	186.45	(167.88)	(31.82)	(91.27)	38.54
	Net income	—	—	—	—	—	—	—	—	—	—
	Depreciation	—	—	—	—	—	—	—	—	—	—
Per share, $
Per share, $	Revenue	70.25	72.84	76.73	77.46	85.52	97.97	94.08	91.45	90.97	94.75
	Earnings	0.96	3.87	12.10	58.93	127.86	142.33	(121.79)	(21.82)	(65.36)	27.87
	Cash flow	7.34	3.51	9.57	15.34	19.65	22.44	6.53	12.84	16.13	19.52
	Capex	(4.80)	(3.88)	(4.21)	(3.00)	(3.53)	(4.48)	(3.83)	(5.36)	(5.87)	(5.78)
	Free cash flow	2.54	(0.37)	5.36	12.34	16.12	17.96	2.70	7.48	10.27	13.74
	Book value	87.61	98.81	134.75	192.84	331.90	458.76	322.82	299.26	232.84	273.40
	Shares, m	29	30	30	30	30	30	30	29	28	27
Valuation, ×
Valuation, ×	P/E	190.53	62.54	19.07	6.28	4.56	5.30	0.00	0.00	0.00	10.84
	P/S	2.60	3.31	3.03	4.78	6.82	7.71	4.49	3.59	3.61	3.20
	P/B	2.09	2.44	1.72	1.92	1.76	1.65	1.31	1.10	1.41	1.11
	EV/Sales	2.41	3.16	2.85	4.48	6.43	7.42	4.28	3.43	3.43	3.07
	EV/FCF	66.48	(619.06)	40.74	28.13	34.11	40.20	142.98	41.59	30.19	21.03
Cash, $m
Cash, $m	Operating cash flow	216	104	285	458	585	669	194	375	455	532
	Capex	(141)	(115)	(126)	(90)	(105)	(134)	(114)	(156)	(165)	(157)
	Free cash flow	75	(11)	160	368	480	536	80	218	290	375
Balance, $m
Balance, $m	Working capital	1,373	1,474	1,573	1,275	1,508	1,310	2,589	2,526	2,563	2,389
	Total debt	434	435	439	440	14	11	1,198	1,200	1,202	1,203
	Net debt	(410)	(326)	(411)	(680)	(983)	(864)	(598)	(413)	(463)	(338)
	Shareholders’ equity	2,579	2,930	4,020	5,755	9,880	13,685	9,615	8,741	6,569	7,454
Returns, %
Returns, %	ROA	0.69	3.01	7.40	25.83	36.36	27.65	(23.18)	(4.94)	(17.03)	7.62
	ROIC	1.61	2.86	(1.79)	2.83	2.96	2.44	3.34	2.54	2.75	0.41
	ROE	1.03	4.44	10.52	35.98	48.79	36.11	(31.14)	(6.94)	(24.09)	10.84

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
PEN Penumbra, Inc.	$12.7B	78.4×	63.5×	+14.90% (above 0%: growing)	−24.79% (below 0%: shrinking)	+10.81% (above 0%: growing)	67.93%	10.52%	Compare
SNN Smith & Nephew SNATS, Inc.	$12.2B	35.4×	18.6×	+7.99% (above 0%: growing)	−14.23% (below 0%: shrinking)	+293.94% (above 0%: growing)	69.42%	0.00%	Compare
GMED Globus Medical, Inc.	$10.6B	19.3×	20.3×	+5.94% (above 0%: growing)	−25.33% (below 0%: shrinking)	+571.30% (above 0%: growing)	69.42%	23.10%	Compare
BIO.B Bio-Rad Laboratories, Inc.	$10.3B	43.7×	—	−0.09% (below 0%: shrinking)	+19.02% (above 0%: growing)	−6.06% (below 0%: shrinking)	53.12%	11.15%	Compare
GKOS Glaukos Corporation	$9.8B	— (loss-making)	— (loss-making)	+49.54% (above 0%: growing)	n/m	+211.83% (above 0%: growing)	81.67%	(9.30%)	Compare
BIO Bio-Rad Laboratories, Inc.	$9.8B	42.5×	35.4×	−0.09% (below 0%: shrinking)	+19.02% (above 0%: growing)	−6.06% (below 0%: shrinking)	53.12%	11.15%
PODD Insulet Corporation	$9.6B	26.4×	24.7×	+23.51% (above 0%: growing)	+328.13% (above 0%: growing)	−70.51% (below 0%: shrinking)	70.18%	16.18%	Compare
BRKR Bruker Corporation	$8.6B	— (loss-making)	55.7×	+5.15% (above 0%: growing)	n/m	+28.63% (above 0%: growing)	49.61%	(7.79%)	Compare
HAE Haemonetics Corporation	$5.5B	57.7×	18.0×	+5.60% (above 0%: growing)	+2.86% (above 0%: growing)	+220.38% (above 0%: growing)	59.76%	16.93%	Compare
Median of peers	$10.0B	39.6×	22.5×	+6.97%	−5.69%	+120.23%	68.68%	10.84%

All 149 Medical Devices stocks →

Bio-Rad Laboratories, Inc. (BIO) key facts

Strength: Bio-Rad Laboratories, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.6 billion, up 0.65% from fiscal 2024.
Bio-Rad Laboratories, Inc. (BIO) is a Medical Devices company in the Healthcare sector, listed on the New York Stock Exchange.
As of October 16, 2026, BIO traded at $353.70, a market capitalization of $9.8 billion.
Return on equity was 10.8% and debt-to-equity 0.17.
Its Piotroski F-score is 5 out of 9 and its Altman Z-score is 3.20 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.